Endometriosis-Pipeline Review, H1 2017

Endometriosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9221IDB
  • |
  • Pages: 128
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Endometriosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis-Pipeline Review, H1 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. The predisposing factors uterine abnormalities, History of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 6, 1, 17, 7 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).

The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Endometriosis-Overview 7

Endometriosis-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Endometriosis-Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Endometriosis-Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Addex Therapeutics Ltd 28

APAvadis Biotechnologies Srl 28

Astellas Pharma Inc 29

Bayer AG 29

Dongkook Pharmaceutical Co Ltd 30

ElexoPharm GmbH 30

EndoCeutics Inc 31

Enteris BioPharma Inc 31

Evotec AG 32

Forendo Pharma Ltd 32

Kissei Pharmaceutical Co Ltd 33

Lipicard Technologies Ltd 33

Luye Pharma Group Ltd 34

Nippon Shinyaku Co Ltd 34

Ogeda SA 35

Orphagen Pharmaceuticals Inc 35

Philogen SpA 36

Repros Therapeutics Inc 36

SK Chemicals Co Ltd 37

Takeda Pharmaceutical Company Ltd 37

ValiRx Plc 38

Viramal Ltd 38

Endometriosis-Drug Profiles 39

acolbifene hydrochloride + GnRH Agonist + prasterone-Drug Profile 39

ADX-68692-Drug Profile 40

ASP-1707-Drug Profile 41

BAY-1128688-Drug Profile 42

BAY-1158061-Drug Profile 43

danazol-Drug Profile 44

Drug 1 for Endometriosis-Drug Profile 45

Drug 2 for Endometriosis-Drug Profile 46

Drug 3 for Endometriosis-Drug Profile 47

Drug 4 for Endometriosis-Drug Profile 48

Drug 5 for Endometriosis-Drug Profile 49

Drug to Antagonize P2X3 for Endometriosis-Drug Profile 50

Drug to Inhibit C-Jun for Endometriosis-Drug Profile 51

Drugs for Endometriosis and Uterine Fibroids-Drug Profile 52

EC-313-Drug Profile 53

elagolix sodium-Drug Profile 54

EVE-104-Drug Profile 59

fezolinetant-Drug Profile 60

FP-5677-Drug Profile 63

goserelin biosimilar-Drug Profile 64

goserelin ER-Drug Profile 65

KLH-2109-Drug Profile 66

leuprolide acetate-Drug Profile 68

LT-6121-Drug Profile 69

MIA-602-Drug Profile 70

NHP-07-Drug Profile 71

NS-580-Drug Profile 72

Peptides for Endometriosis and Hepatic Tumor-Drug Profile 73

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor-Drug Profile 74

PGL-2001-Drug Profile 75

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome-Drug Profile 76

relugolix-Drug Profile 77

SKI-2670-Drug Profile 80

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile 81

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology-Drug Profile 82

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 83

Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology-Drug Profile 84

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 85

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 86

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 87

Small Molecules to Inhibit HSD17B1 for Endometriosis-Drug Profile 88

SR-16234-Drug Profile 89

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy-Drug Profile 90

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 91

telapristone acetate-Drug Profile 92

Tetravil-Drug Profile 101

TOT-206-Drug Profile 103

triptorelin acetate ER-Drug Profile 104

triptorelin biosimilar-Drug Profile 105

VAL-301-Drug Profile 106

vilaprisan-Drug Profile 107

VPE-001-Drug Profile 108

VPEA-004-Drug Profile 109

Endometriosis-Dormant Projects 110

Endometriosis-Discontinued Products 112

Endometriosis-Product Development Milestones 113

Featured News & Press Releases 113

Appendix 123

Methodology 123

Coverage 123

Secondary Research 123

Primary Research 123

Expert Panel Validation 123

Contact Us 123

Disclaimer 124

List of Figures

Number of Products under Development for Endometriosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Endometriosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Endometriosis-Pipeline by AbbVie Inc, H1 2017

Endometriosis-Pipeline by Addex Therapeutics Ltd, H1 2017

Endometriosis-Pipeline by APAvadis Biotechnologies Srl, H1 2017

Endometriosis-Pipeline by Astellas Pharma Inc, H1 2017

Endometriosis-Pipeline by Bayer AG, H1 2017

Endometriosis-Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Endometriosis-Pipeline by ElexoPharm GmbH, H1 2017

Endometriosis-Pipeline by EndoCeutics Inc, H1 2017

Endometriosis-Pipeline by Enteris BioPharma Inc, H1 2017

Endometriosis-Pipeline by Evotec AG, H1 2017

Endometriosis-Pipeline by Forendo Pharma Ltd, H1 2017

Endometriosis-Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Endometriosis-Pipeline by Lipicard Technologies Ltd, H1 2017

Endometriosis-Pipeline by Luye Pharma Group Ltd, H1 2017

Endometriosis-Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Endometriosis-Pipeline by Ogeda SA, H1 2017

Endometriosis-Pipeline by Orphagen Pharmaceuticals Inc, H1 2017

Endometriosis-Pipeline by Philogen SpA, H1 2017

Endometriosis-Pipeline by Repros Therapeutics Inc, H1 2017

Endometriosis-Pipeline by SK Chemicals Co Ltd, H1 2017

Endometriosis-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Endometriosis-Pipeline by ValiRx Plc, H1 2017

Endometriosis-Pipeline by Viramal Ltd, H1 2017

Endometriosis-Dormant Projects, H1 2017

Endometriosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Endometriosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, Addex Therapeutics Ltd, APAvadis Biotechnologies Srl, Astellas Pharma Inc, Bayer AG, Dongkook Pharmaceutical Co Ltd, ElexoPharm GmbH, EndoCeutics Inc, Enteris BioPharma Inc, Evotec AG, Forendo Pharma Ltd, Kissei Pharmaceutical Co Ltd, Lipicard Technologies Ltd, Luye Pharma Group Ltd, Nippon Shinyaku Co Ltd, Ogeda SA, Orphagen Pharmaceuticals Inc, Philogen SpA, Repros Therapeutics Inc, SK Chemicals Co Ltd, Takeda Pharmaceutical Company Ltd, ValiRx Plc, Viramal Ltd

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com